Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02315131
Other study ID # TV46017-COPD-10046
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date March 2015
Est. completion date August 2015

Study information

Verified date November 2021
Source Teva Branded Pharmaceutical Products R&D, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV46017


Recruitment information / eligibility

Status Terminated
Enrollment 53
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 75 Years
Eligibility Stage 1 Inclusion Criteria (healthy volunteers): - The subject is a male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg with a body mass index (BMI) of less than 30 kg/m2. Note: Every effort should be made to enroll approximately equal numbers of men and women in each group. - The subject is in good health as determined by medical and psychiatric history, physical examination, electrocardiogram (ECG), serum chemistry, hematology, urinalysis, and serology. - Other criteria apply, please contact the investigator for more information Stage 2 Inclusion Criteria (COPD patients): - Current or former cigarette smokers with a history of cigarette smoking of =10 pack years at the SV (number of cigarette packs smoked per day multiplied by the number of years smoked; eg, 2 packs/day for 3 years equals a 6 pack year history). - Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines. - Male or female; 40 to 75 years of age, inclusive. - Patient is free of any other medical conditions or concomitant treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study. - Other criteria apply, please contact the investigator for more information Stage 1 Exclusion Criteria (healthy volunteers): - History or current evidence of a clinically significant or uncontrolled disease. - Any disorder that may interfere with the absorption, distribution, metabolism or excretion of study drugs. - History of severe allergy to milk protein. - Active smokers or former smokers who quit within 3 months of the first dose of study drug. Former smokers with greater than five-pack years (ie, the equivalent of one pack per day for five years) are also excluded. - Other criteria apply, please contact the investigator for more information Stage 2 Exclusion Criteria (COPD patients): - Recent history of hospitalization due to an exacerbation of airway disease within 3 months. - Need for increased treatments of COPD within 6 weeks prior to the SV. - Occurrence of a COPD exacerbation, which is not resolved by 4 weeks or more prior to the SV/informed consent. (Note: An exacerbation of COPD is defined as any worsening of the patient's baseline COPD symptoms requiring any treatment other than rescue albuterol or the patient's regular maintenance therapy. This includes requiring the use of systemic corticosteroids, antibiotics, and/or emergency room visit or hospitalization.) - History of and/or current diagnosis of asthma. - Known a1 antitrypsin deficiency, active lung infections (such as tuberculosis or pneumonia), and lung cancer are absolute exclusionary conditions. A patient who, in the opinion of the investigator, has any other significant respiratory condition in addition to COPD should be excluded. Examples may include clinically significant noncystic bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease. Allergic rhinitis is not exclusionary. - Other criteria apply, please contact the investigator for more information

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TV46017
TV46017 15, 60, 120, and 240 µg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
Placebo
Placebo Comparator

Locations

Country Name City State
Australia Teva Investigational Site 78984 Adelaide
Australia Teva Investigational Site 78985 Nedlands
New Zealand Teva Investigational Site 79037 Auckland
New Zealand Teva Investigational Site 79036 Hamilton
New Zealand Teva Investigational Site 79034 Wellington
United States Teva Investigational Site 13034 Raleigh North Carolina
United States Teva Investigational Site 13033 Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Countries where clinical trial is conducted

United States,  Australia,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary FEV1 AUC0-12h baseline adjusted forced expiratory volume in 1 second area under the curve over 12 hours Baseline, 12 hours
Secondary FEV1 baseline adjusted trough 12 hour Baseline, 12 hours
Secondary Percentage of Participants with Adverse Events 28 Days
See also
  Status Clinical Trial Phase
Completed NCT04684836 - Comparative Effectiveness of Telemedicine in Primary Care
Active, not recruiting NCT04966637 - Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data
Recruiting NCT04195191 - Intervention to Improve the Adherence in Community Pharmacies N/A
Completed NCT02864342 - Adherence Study in COPD Patients Phase 4
Completed NCT03639220 - Photobiomodulation Therapy in Exercise Capacity Assessed by 6MST in Patients With COPD N/A